Novavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its position in Novavax, Inc. (NASDAQ:NVAX) by 19.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 935,813 shares of the biopharmaceutical company’s stock after selling 223,154 shares during the period. SG Americas Securities LLC owned approximately 0.58% of Novavax worth $5,999,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Sanofi acquired a new stake in Novavax in the 4th quarter valued at approximately $55,319,000. Deep Track Capital LP bought a new position in shares of Novavax in the fourth quarter worth $16,080,000. BNP Paribas Financial Markets increased its holdings in shares of Novavax by 289.0% during the fourth quarter. BNP Paribas Financial Markets now owns 556,832 shares of the biopharmaceutical company’s stock valued at $4,477,000 after purchasing an additional 413,676 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of Novavax during the fourth quarter valued at about $2,761,000. Finally, ExodusPoint Capital Management LP bought a new position in Novavax in the 4th quarter valued at about $2,687,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

Novavax Price Performance

NASDAQ NVAX opened at $7.15 on Friday. The company has a market capitalization of $1.16 billion, a P/E ratio of -3.16, a PEG ratio of 2.85 and a beta of 2.81. Novavax, Inc. has a 12 month low of $5.01 and a 12 month high of $17.81. The company’s 50 day simple moving average is $6.70 and its 200 day simple moving average is $7.73.

Novavax (NASDAQ:NVAX) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $2.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $2.22. The company had revenue of $666.66 million during the quarter, compared to analysts’ expectations of $204.08 million. The company’s revenue for the quarter was up 610.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.05) EPS. On average, analysts anticipate that Novavax, Inc. will post -1.46 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. reduced their price target on shares of Novavax from $9.00 to $7.00 and set an “underweight” rating for the company in a research note on Friday, May 9th. TD Cowen raised Novavax to a “hold” rating in a report on Thursday, February 27th. BTIG Research assumed coverage on Novavax in a research note on Friday, February 28th. They set a “buy” rating and a $19.00 price target for the company. Finally, B. Riley reiterated a “buy” rating on shares of Novavax in a research report on Monday, May 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $19.00.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.